- Home
- PROK vs NODK Comparison
PROK vs NODK Comparison
Compare PROK & NODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PROK | NODK |
|---|---|---|
| Founded | 2015 | 1946 |
| Country | United States | United States |
| Employees | 231 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 265.8M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PROK | NODK |
|---|---|---|
| Price | $1.81 | $12.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.40 | N/A |
| AVG Volume (30 Days) | ★ 795.9K | 21.5K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $893,000.00 | ★ $285,050,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $0.46 | $12.01 |
| 52 Week High | $7.13 | $14.70 |
Technical Indicators
Market Signals| Indicator | PROK | NODK |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 41.44 |
| Support Level | $1.71 | $12.39 |
| Resistance Level | $2.58 | $13.70 |
| Average True Range (ATR) | 0.14 | 0.44 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 42.97 | 18.70 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. Through its subsidiaries, the company operates in the insurance industry, offering homeowners and farmowners insurance policies, crop insurance policies, home insurance policies, etc. These insurance products are distributed through a network of exclusive and independent agents across the United States. The group's reportable segments are: Private Passenger Auto, Non-Standard Auto, Home and Farm, Crop, and All Other (which mainly consists of commercial, assumed reinsurance, and its excess liability business). Maximum revenue is generated from the Home and Farm segment.